When many cancers advance, spread and reoccur, checkpoint inhibitors can help keep difficult tumors at bay. These antibody-based immunotherapies can restore the body’s ability to recognize and ...

First-line treatment of advanced acral melanoma with the PD-1 inhibitor toripalimab (Loqtorzi) resulted in a small but ...

Hutchmed's fruquintinib and Eli Lilly & Innovent Biologics' Tyvyt (sintilimab) significantly improved PFS during a Phase III trial in second-line renal cell carcinoma (RSS). Image credit: Kateryna Kon ...

PD-1 checkpoint proteins on T cells (blue) can bind to two different receptors: PD-L1 and PD-L2. There are many ways to climb a mountain. This saying especially rings true in cancer research, where ...

Use of a neoadjuvant checkpoint inhibitor enabled a high proportion of patients with early-stage mismatch repair-deficient (dMMR) solid tumors to avoid surgery and achieve organ preservation in a ...

Though Pfizer Inc.’s work on a PD-1-targeting antibody has trailed far behind that of its fellow big pharmas, the company could be the first to market in treatment-naïve, high-risk non-muscle invasive ...